DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zytiga (Abiraterone Acetate) - Published Studies

 
 



Zytiga Related Published Studies

Well-designed clinical trials related to Zytiga (Abiraterone)

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. [2013]

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. [2012]

Well-designed clinical trials possibly related to Zytiga (Abiraterone)

Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. [2013]

Other research related to Zytiga (Abiraterone)

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. [2013]

Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. [2012]

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. [2012]

Other possibly related research studies

Management of metastatic castration-resistant prostate cancer: recent advances. [2012]

Chemotherapy-based treatment for castration-resistant prostate cancer. [2011]

Pharmacotherapeutic management of locally advanced prostate cancer: current status. [2011]

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. [2011]

Current clinical trials in castrate-resistant prostate cancer. [2011]

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. [2009]

Therapies in development for castrate-resistant prostate cancer. [2008]

Intermittent androgen deprivation therapy in advanced prostate cancer. [2014]

Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. [2014]

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. [2014]

The changing landscape in metastatic castration-resistant prostate cancer. [2013]

Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? [2013]

New agents in the arsenal to fight castrate-resistant prostate cancer. [2013]

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. [2013]

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. [2014]

Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. [2014]

The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. [2014]

Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. [2014]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017